Omebeta (Omeprazole)

Omeprazole, the active ingredient in Omebeta, is a proton pump inhibitor presented as a tablet for oral use. It reduces stomach acid production and is used to treat acid‑related gastrointestinal conditions in adults and children. GNH USA supplies Omebeta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Omebeta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omeprazole acts on the gastric acid secretion pathway and is indicated for several acid‑related disorders.

- Gastro‑esophageal reflux disease (GERD): provides symptomatic relief and promotes healing of erosive esophagitis. - Peptic ulcer disease: supports ulcer healing and reduces recurrence risk. - Zollinger‑Ellison syndrome: controls excessive gastric acid secretion. - Helicobacter pylori eradication regimens: used as part of combination therapy to improve eradication rates. - NSAID‑associated ulcer prevention: lowers the risk of ulcer development in at‑risk patients.

Adverse reactions to omeprazole vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: typically self‑limiting. - Nausea: occasional and transient. - Abdominal pain: mild discomfort. - Flatulence: excess gas. - Constipation: infrequent.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis risk. - Acute interstitial nephritis: renal inflammation. - Hypomagnesemia: low serum magnesium levels. - Stevens‑Johnson syndrome: severe skin reaction. - Fracture risk: possible reduction in bone mineral density with long‑term use. - Liver enzyme elevation: increased ALT/AST.

When prescribing omeprazole, clinicians should consider several safety aspects.

- Assess renal function: dose adjustment may be needed in severe impairment. - Review concomitant medications: potential for drug‑drug interactions. - Monitor long‑term use: evaluate need for continued therapy after several months. - Counsel on infection risk: inform patients about possible increased susceptibility to gastrointestinal infections. - Evaluate bone health: consider calcium and vitamin D supplementation for at‑risk patients. - Store at ambient temperature: keep in the original container, protect from moisture and heat.

Omeprazole may interact with a range of medicines, altering their effectiveness or safety.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet activity. - Atazanavir: decreased antiviral absorption. - Dasatinib: lowered plasma concentrations.

Moderate Interactions (Monitor Closely): - Warfarin: potential INR elevation. - Phenytoin: increased metabolism leading to reduced seizure control. - Digoxin: higher serum levels may occur. - Ketoconazole: impaired absorption due to reduced acidity.